Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
Rongbo Lin, Fuzhou, Fujian, China
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Beijing Youan Hospital,Capital Medical University, Beijing, Beijing, China
Beijing Youan Hospital,Capital Medical University, Beijing, Beijing, China
Sheba Medical Center, Ramat Gan, Israel
University of Virginia Cancer Center, Charlottesville, Virginia, United States
the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
CHRU de Lille - Hôpital Roger Salengro, Lille, France
CHU de Limoges - Hôpital Dupuytren, Limoges, France
HCL - Hôpital Neurologique P. Wertheimer, Lyon, France
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.